Bonus Biogroup develops innovative technologies that harness adipose-derived stromal cells to treat diseases involving tissue damage, inflammation, and autoimmunity. Their cell therapy and tissue engineering approaches offer comprehensive treatment solutions.

Bonus Biogroup

Bonus Biogroup | 5,443 followers on LinkedIn. Innovation ★ Tissue Engineering ★ Cell Therapy ★ Impact | Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company engaged in the R&amp;D of tissue-engineered and cell therapy products. Bonus CEO Dr. Shai Meretzki, one of Israel&#39;s most prominent biotech entrepreneurs, founded Bonus to build live tissues outside the body.

Head Of Research @ Bonus BioGroup | Ph.D in Biomedical Engineering

Yulia Shandalov-Levi

Vice President for Innovation & Corporate Development @ Bonus Biogroup

Tomer Bronshtein

VP Regulatory and Clinical Affairs at Bonus BioGroup

Vered Kivity

𝐂𝐄𝐎 𝐚𝐭 𝐏𝐫𝐨𝐏𝐡𝐚𝐫𝐦𝐚 𝐥𝐭𝐝. 𝐃𝐢𝐫𝐞𝐜𝐭𝐨𝐫 𝐛𝐨𝐧𝐮𝐬 𝐁𝐢𝐨𝐠𝐫𝐨𝐮𝐩

Gil Shapira

🌟 𝐌𝐚𝐣𝐨𝐫 𝐌𝐢𝐥𝐞𝐬𝐭𝐨𝐧𝐞 𝐀𝐥𝐞𝐫𝐭! 🌟 We’re thrilled to announce that Bonus Biogroup has received official certification from the Israel Ministry of Health confirming that our two flagship products— #BonoFill (live human bone graft) and #MesenCure (advanced cellular therapy)—are produced in full compliance with Good Manufacturing Practices (GMP), in line with the recommendations of the World Health Organization! This certification not only reflects the highest quality standards but also paves the way for our journey toward industrial-scale production of these innovative therapies. 𝐖𝐡𝐚𝐭 𝐓𝐡𝐢𝐬 𝐌𝐞𝐚𝐧𝐬: 🔹 BonoFill and MesenCure production processes meet rigorous GMP standards for phase III clinical trials, opening new doors for advanced supply chain management and operational independence. 🔹 Our Haifa-based facility, designed for automated and sterile cell and tissue production, is now fully certified, ensuring consistent product quality and enhanced safety. Dr. Shai Meretzki, CEO, expressed it best: "𝐓𝐡𝐞𝐬𝐞 𝐆𝐌𝐏 𝐜𝐞𝐫𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐧𝐨𝐭 𝐨𝐧𝐥𝐲 𝐯𝐚𝐥𝐢𝐝𝐚𝐭𝐞 𝐨𝐮𝐫 𝐡𝐢𝐠𝐡 𝐩𝐫𝐨𝐝𝐮𝐜𝐭 𝐪𝐮𝐚𝐥𝐢𝐭𝐲 𝐛𝐮𝐭 𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧 𝐮𝐬 𝐚𝐭 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐟𝐫𝐨𝐧𝐭 𝐨𝐟 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐚𝐧𝐝 𝐭𝐢𝐬𝐬𝐮𝐞 𝐞𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐰𝐨𝐫𝐥𝐝𝐰𝐢𝐝𝐞, 𝐩𝐨𝐢𝐬𝐞𝐝 𝐭𝐨 𝐫𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐞 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐟𝐨𝐫 𝐦𝐢𝐥𝐥𝐢𝐨𝐧𝐬." #MedicalInnovation #BiotechInnovation #Biotechnology #RegenerativeMedicine #GMP #CellTherapy #TissueEngineering #HealthcareInnovation #LifeSciences

𝗕𝗼𝗻𝘂𝘀 𝗕𝗶𝗼𝗴𝗿𝗼𝘂𝗽 𝗶𝘀 𝗱𝗲𝗹𝗶𝗴𝗵𝘁𝗲𝗱 𝘁𝗼 𝗮𝘁𝘁𝗲𝗻𝗱 𝘁𝗵𝗲 𝟭𝟯𝘁𝗵 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗼𝗳 𝘁𝗵𝗲 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗦𝗼𝗰𝗶𝗲𝘁𝘆 𝗳𝗼𝗿 𝗔𝗽𝗽𝗹𝗶𝗲𝗱 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 ( #𝗜𝗦𝗔𝗕𝗦𝟮𝟬𝟮𝟰 ) 𝗶𝗻 𝗦𝗽𝗹𝗶𝘁, 𝗖𝗿𝗼𝗮𝘁𝗶𝗮. We extend our gratitude to the organizing committee and ISABS President Prof. Dragan Primorac, M.D., Ph.D. , for inviting us to present our results from clinical trials for the company's two advanced products, #BonoFill and #MesenCure . 𝗜𝘁 𝗶𝘀 𝗮𝗻 𝗵𝗼𝗻𝗼𝗿 𝘁𝗼 𝘀𝗵𝗮𝗿𝗲 𝗼𝘂𝗿 𝗰𝗼𝗻𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗿𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝘃𝗶𝗮 𝗰𝗲𝗹𝗹𝘀 𝗮𝗻𝗱 𝘁𝗶𝘀𝘀𝘂𝗲 𝗽𝗿𝗶𝗺𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗮 𝗱𝗶𝘀𝘁𝗶𝗻𝗴𝘂𝗶𝘀𝗵𝗲𝗱 𝗮𝘂𝗱𝗶𝗲𝗻𝗰𝗲, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗡𝗼𝗯𝗲𝗹 𝗟𝗮𝘂𝗿𝗲𝗮𝘁𝗲𝘀 𝗣𝗿𝗼𝗳. 𝗚𝗿𝗲𝗴𝗴 𝗦𝗲𝗺𝗲𝗻𝘇𝗮 (𝗡𝗼𝗯𝗲𝗹 𝗣𝗿𝗶𝘇𝗲 𝗶𝗻 𝗣𝗵𝘆𝘀𝗶𝗼𝗹𝗼𝗴𝘆 𝗮𝗻𝗱 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝟮𝟬𝟭𝟵), 𝗣𝗿𝗼𝗳. 𝗥𝗶𝗰𝗵𝗮𝗿𝗱 𝗥𝗼𝗯𝗲𝗿𝘁𝘀 (𝗡𝗼𝗯𝗲𝗹 𝗣𝗿𝗶𝘇𝗲 𝗶𝗻 𝗣𝗵𝘆𝘀𝗶𝗼𝗹𝗼𝗴𝘆 𝗮𝗻𝗱 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝟭𝟵𝟵𝟯), 𝗮𝗻𝗱 𝗣𝗿𝗼𝗳. 𝗦𝘃𝗮𝗻𝘁𝗲 𝗣𝗮𝗮𝗯𝗼 (𝗡𝗼𝗯𝗲𝗹 𝗣𝗿𝗶𝘇𝗲 𝗶𝗻 𝗣𝗵𝘆𝘀𝗶𝗼𝗹𝗼𝗴𝘆 𝗮𝗻𝗱 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝟮𝟬𝟮𝟮). Bonus Biogroup's presentation, delivered by our VP of Regulatory & Clinical Affairs, Dr. Vered Kivity , was part of a series of lectures on translational medicine in collaboration with the Mayo Clinic . Pursuant to an outline agreed upon with the U.S. FDA, we were thrilled to announce during the ISABS meeting that the company has successfully completed the development of a unique potency test for MesenCure, a cell therapy drug for treating inflammation and tissue damage. In developing this test, the Company achieved an essential milestone for transitioning from Phase II to Phase III clinical trials in the United States for the treatment of respiratory distress in severely ill patients using MesenCure. For more information >>> https://lnkd.in/dd2sCSGY #medicalinnovation #biotechinnovation #tissueengineering #regenerativemedicine #biotechnology #celltherapy

🌟 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗳𝗼𝗿 𝗕𝗼𝗻𝘂𝘀 𝗕𝗶𝗼𝗴𝗿𝗼𝘂𝗽! 🌟 We are thrilled to announce complete success in bone reconstruction in 90% of transplants in our Phase II clinical trial using #BonoFill – a live human bone graft! This remarkable achievement was presented at the annual meeting of the ISCT, International Society for Cell & Gene Therapy in Vancouver, Canada. Key Highlights: 𝟵𝟬% 𝗦𝘂𝗰𝗰𝗲𝘀𝘀 𝗥𝗮𝘁𝗲: BonoFill™ achieved natural and complete jawbone reconstruction in 90% of the transplants. 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲𝗱 𝗛𝗲𝗮𝗹𝗶𝗻𝗴: Patients experienced up to two-thirds reduction in healing time, allowing them to return to their normal routine faster. 𝗪𝗶𝗱𝗲 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝗯𝗶𝗹𝗶𝘁𝘆: BonoFill™'s success is independent of patient weight, age, gender, or bone condition. This groundbreaking innovation not only enhances patient recovery but also simplifies the treatment process, making it accessible in dental clinics without the need for complex surgeries. Dr. Shai Meretzki, Ph.D , CEO of Bonus Biogroup, stated, "This milestone positions us as a world leader in tissue engineering and cellular medicine. Our vision is to help millions of patients live healthier, longer lives." Dr. Ephraim Tzur , who led the clinical trial, highlighted, "BonoFill™ offers a stronger, more reliable solution for facial bone deficiencies, paving the way for better rehabilitative procedures." Read more about our innovative advancements and future plans with BonoFill™ and MesenCure™ 🔗 https://lnkd.in/dApNb8wP #medicalinnovation #biotechinnovation #tissueengineering #regenerativemedicine #biotechnology #celltherapy #bone #ISCT2024

I can't wait to present the final results of our Phase II clinical trial for treating facial bone deficiencies using #BonoFill , our Mesenchymal Cell-Based Bone Tissue Engineering product, tomorrow at the ISCT, International Society for Cell & Gene Therapy annual meeting in Vancouver, Canada! Join me at the MSC Oral Abstract Session on Friday, May 31, 2024, at 8 AM PT as I share our groundbreaking advancements in regenerative medicine and biotechnology. This is a significant milestone for Bonus Biogroup , and I am proud to represent our team's continuous achievements in the field. Stay tuned for more updates! For more information >>> https://lnkd.in/dAAgjzW9 #medicalinnovation #biotechinnovation #tissueengineering #regenerativemedicine #biotechnology #celltherapy #bone

𝐁𝐨𝐧𝐮𝐬 𝐁𝐢𝐨𝐠𝐫𝐨𝐮𝐩 𝐢𝐬 𝐭𝐡𝐫𝐢𝐥𝐥𝐞𝐝 𝐭𝐨 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐭𝐡𝐚𝐭 𝐰𝐞 𝐡𝐚𝐯𝐞 𝐛𝐞𝐞𝐧 𝐢𝐧𝐯𝐢𝐭𝐞𝐝 𝐭𝐨 𝐩𝐫𝐞𝐬𝐞𝐧𝐭 𝐭𝐡𝐞 𝐟𝐢𝐧𝐚𝐥 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐨𝐟 𝐨𝐮𝐫 𝐏𝐡𝐚𝐬𝐞 𝐈𝐈 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥 𝐥𝐞𝐝 𝐛𝐲 𝐃𝐫. Ephraim Tzur 𝐟𝐨𝐫 𝐭𝐫𝐞𝐚𝐭𝐢𝐧𝐠 𝐟𝐚𝐜𝐢𝐚𝐥 𝐛𝐨𝐧𝐞 𝐝𝐞𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐢𝐞𝐬 𝐮𝐬𝐢𝐧𝐠 #𝐁𝐨𝐧𝐨𝐅𝐢𝐥𝐥 . The results will be presented at the prestigious ISCT, International Society for Cell & Gene Therapy annual meeting #ISCT2024 in Vancouver, Canada. Join us on May 31, 2024, as we share groundbreaking advancements in regenerative medicine and biotechnology. Our innovative live human bone graft, BonoFill™, is making waves in the field, and we are proud to be recognized for our continuous achievements. Dr. Shai Meretzki, CEO, highlights this milestone as a testament to our commitment to developing next-generation treatments and our vision for patient well-being. Stay tuned for more updates as we continue to lead the way in biotechnology and cell therapy innovation! For more information >>> https://lnkd.in/dAAgjzW9 #medicalinnovation #biotechinnovation #tissueengineering #regenerativemedicine #biotechnology #celltherapy #bone

At Bonus Biogroup, we are proud and privileged to have Dr. Limor Kaneti on our team, leading our Methods Development & Validation Department, making strides every day to improve the lives of patients. Thank you, Limor, for being so bright and nice.

Thank you, NoCamels - Israeli Tech & Innovation News for sharing the exciting story of #BonoFill our innovation that saves limbs.

פטנטים בעולם הביוטכנולוגיה הם כלי רב עוצמה לקידום חדשנות. עם זאת, חשוב להיות מודעים למורכבות והאתגרים הכרוכים בהם. אנו שמחים לשתף את מאמרם של ד"ר תומר ברונשטיין, סמנכ"ל חדשנות ופיתוח תאגידי בבונוס ביוגרופ וד"ר אסף גרא, שותף במשרד גרא, קסטן פרידמן לזכויות יוצרים על חדשנות ואתגרים בפטנטים בביוטכנלוגיה >> https://lnkd.in/dtsGSpVJ Tomer Bronshtein Assaf Geyra #biotechnology #innovation #patents

Thank you, ISRAEL21c — Good News From Israel , for sharing our story of innovation that promises to improve the success rate of organ engineering and transplants, opening new horizons in regenerative medicine >>> https://lnkd.in/dvWxvzfn #medicalinnovation #biotechinnovation #tissueengineering #regenerativemedicine #organtransplant #lifesciences #healthcareinnovation #biotechnology

The #biotech sector is buzzing with a $6.2 billion fundraising surge in January, the highest since 2021! While early-stage ventures see cautious optimism, success stories like Kyverna Therapeutics ' IPO signal growing investor confidence and a potential wider market rebound. Could this be the start of a new era for biotech? Read more: https://lnkd.in/ej7jJGAf

Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS, as well as other life-threatening acute inflammatory diseases. Its products in pipeline comprise bone augmentation in osteoporosis patients; novel nano-materials for drug delivery; vascularized bone grafts; and soft tissue grafts. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel.

news impact assignment basic	general
public peers	general	Nov 11, 2024 9:10 AM	07ceb404
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 11, 2024 9:10 AM	78931988
crunchbase trigger	general	Nov 27, 2024 12:50 PM	6eebf831
crunchbase profile	general
li profile	general	Nov 11, 2024 9:10 AM	5959a9b4
translate crunchbase fundingrounds	general
peers	general	Nov 11, 2024 9:10 AM	91613af7
news basic	general	Nov 11, 2024 9:10 AM	9d0a9cb1
bundesanzeiger	filings
financials download nd	financials
private financials	financials

BONS

COM:BONUS-BIO

Bonus Biogroup

Last Close

11.20

25/11 09:15

Market Cap

181.03M

Beta: -

Volume Today

303.68K

Avg: -